

**S3 Table.** Baseline characteristics of subgroup according to targeted treatment; patients who received TKIs treatment (target Tx; n=117) vs. who did not (no target; n=59)

<b>Variable</b>	<b>No target (n=59)</b>	<b>Target Tx (n=117)</b>	<b>p-value</b>
Age (yr)	61.6±9.5	59.4±11.0	0.19
Female sex	23 (39.0)	61 (52.1)	0.14
Body mass index	23.8±3.0	24.2±2.7	0.43
Diabetes mellitus	6 (10.2)	12 (10.3)	> 0.99
Hypertension	18 (30.5)	39 (33.3)	0.84
Pulmonary tuberculosis	8 (13.6)	8 (6.8)	0.24
Never smoker	27 (45.8)	75 (64.1)	0.03
FEV <sub>1</sub> (%)	85.3±20.7	89.1±17.1	0.20
DLCO (%)	83.2±19.6	89.6±17.7	0.04

Values are presented as mean±SD or number (%). DLCO, diffusing capacity of the lungs for carbon monoxide; FEV<sub>1</sub>, forced expiratory volume in 1 second; TKI, tyrosine kinase inhibitor.